Brief: Enhabit Q2 EPS USD 0.1

Enhabit

06/08/2025 21:15

Overview

Home health and hospice care provider Enhabit Q2 net service revenue grows 2.1% yr/yr to $266.1 mln

Adjusted EBITDA for Q2 beats analyst expectations, rising 6.7% yr/yr

Adjusted EPS of $0.13, exceeding estimates

Outlook

Enhabit updates 2025 revenue guidance to $1,060 mln-$1,073 mln

Company raises 2025 adjusted EBITDA forecast to $104 mln-$108 mln

Enhabit increases 2025 adjusted EPS guidance to $0.47-$0.55

Result Drivers

HOME HEALTH GROWTH - Admissions increased 1.3% yr/yr, aided by payer contract initiatives and stabilization in Medicare Fee-for-Service census

HOSPICE EXPANSION - Hospice average daily census rose 12.3% yr/yr, marking the sixth consecutive qtr of growth

DEBT REDUCTION - Enhabit reduced bank debt by $10 mln, enhancing liquidity and financial stability

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted EPS
Beat
$0.13
$0.1 (6 Analysts)
Q2 EPS
$0.1
Q2 Adjusted EBITDA
Beat
$26.90 mln
$25.20 mln (5 Analysts)
Q2 Gross Margin
49.1%
Q2 Adjusted EBITDA Margin
10.1%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Enhabit Inc is $10.00, about 33.1% above its August 5 closing price of $6.69

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nBw712GZGa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)